SCOLR Pharma, Inc.

Amex:  DDD

Self Correcting Oral Linear Release -

Enabling Technologies for Oral Medications

SCOLR Pharma

TM

TM

CDT®

is a registered trademark of SCOLR Pharma, Inc.

SCOLR & CDT logo and design are trademarks of SCOLR Pharma, Inc.

Exhibit 99.1

SCOLR Pharma, Inc.

Amex:  DDD

Forward-Looking Statements

This

presentation

contains

forward-looking

statements

within

the

meaning

of

the

Private

Securities

Litigation

Reform

Act

of

1995

that

involve

significant

risks

and

uncertainties.

These

statements

represent

management’s

present

expectations

of

future

events

and

are

subject

to

a

number

of

important

factors

that

could

cause

actual

results

to

differ

materially

from

those

described

in

the

forward-looking

statements

including:

The timing of product introductions

Product development & clinical timelines

Availability of Additional Financing

Regulatory approvals and government regulation

Modifications to business strategy

Please

refer

to

the

risk

factors

and

other

cautionary

language

included

in

our

reports

and

other

filings

with

the

Securities

and

Exchange

Commission

and

available

on

our

website.

We

assume

no

obligation

to

update

these

forward-looking

statements.

SCOLR Pharma, Inc.

Amex:  DDD

The SCOLR Opportunity

SCOLR

Pharma™

is

a

specialty pharmaceutical/oral

drug delivery company

Develops, licenses and

commercializes novel products

based on its innovative CDT

platform

Newly patented and broadly

applicable, CDT provides

technological and cost savings

benefits for Pharmaceutical,

OTC and Health Supplement

products

$78 billion global drug delivery

market is expected to double in

five years

Licensing revenues generated

from health supplements

Pharma and OTC formulations

with significant market potential

TM

SCOLR Pharma, Inc.

Amex:  DDD

SCOLR Pharma Overview

Shares

Outstanding: 34.9m

Fully Diluted: 40.3m

Approx. Float: 30.6m

Market Cap. (Jan. 23, ’06)

Approx. $252 million

Cash (Sept. 30, 2005)

$16.2 million   

Experienced Management Team

Development relationship with

Temple University’s Industrial

School of Pharmacy

Board Members with extensive

Regulatory/Pharma/Financial

Expertise

TM

SCOLR Pharma, Inc.

Amex:  DDD

Drug Delivery

Routes*

Oral = 46%

Inhalation

Injectable

Transdermal

Others

What Is Drug Delivery ?

*Datamonitor 2003

Definition:

Technology

utilized

to

improve

the

safety

and

efficacy

of

a

drug

and/or

to

prolong

its

commercial

viability

as

it

goes

off-patent.

U.S. ’05 = $32 billion

Est.

U.S. ’08 = $46.8 billion

SCOLR Pharma, Inc.

Amex:  DDD

Competitive Landscape

*Includes

75

key

drug

delivery

companies

as

identified

through

HA

analysis;

“Other”

refers

to

oral

site-directed,

taste-masking,

buccal

and

peptide

technologies

Sources:

Drug

Delivery

Companies

Report

Summer

2003;

Dorlands

2003,

Frost

and

Sullivan

2001,

Drug

Delivery

Technology

Vol.

3

Num.

3

May

2003.

52

36

62

0

5

10

15

20

25

30

35

40

45

50

55

60

65

70

Controlled/

Sustained

Release

Solubility

Enhancing

Other

Drug Delivery Technology

50

Multiple

Drugs in

Single Dose

23

Fast

Dissolve

SCOLR Pharma, Inc.

Amex:  DDD

Investment Highlights

Revenue

Potential

–

Licensing

Ready

Formulations

Risk Mitigation Factors

Value Driving Opportunities

Historically Rich Market Valuations

SCOLR Pharma, Inc.

Amex:  DDD

Revenue (Current and Potential)

Licensing revenues generated by health supplements 

Note: Alliance with Perrigo

in Oct. 2005

OTC –

1

st

two formulations in Clinical Evaluation

12

hour

Ibuprofen

($8

billion

global

OTC

analgesic

market)

–Potential

to become

the

first

U.S.

Extended

Release

Ibuprofen.

Licensed

CDT

applications

for

ibuprofen

products

to

Wyeth

Consumer

Health

(Dec. 2005).

12

hour

Pseudoephedrine

($1

billion

market)

–

Expect

to

File

ANDA

in 2006.

OTC

–

Other

OTC

Targets

In

Development

Prescription

Drugs

–

Initial

Targets

Identified

–

IR Raloxifene, ER Ondansetron (Combined $2.4 billion existing market)

IR

Raloxifene

-

Pilot

study

completed,

results

positive

24

hour

Ondansetron

–

Pilot

study

dosing

complete,

Data

analysis

Q1, 2006.

Investment Highlights

SCOLR Pharma, Inc.

Amex:  DDD

Risk Mitigation Factors

CDT technology platform based on a portfolio of recently issued and pending

patents applicable to a large number of compounds with significant global

sales

Proven technology

Clinical Testing

24-hour CDT-Niacin

12-hour CDT-Ibuprofen

12-hour CDT-Pseudoephedrine

IR CDT-Raloxifene

ER CDT-Ondansetron

Six

animal

studies

for

“Proof

of

Process”

for

Amino

Acid

Technology

Successful Commercialization

Six Health Supplements currently on market at major retailers

Over

100

million

tablets

shipped

to

date

(Wal-

Mart,

Rite

Aid,

Trader

Joe’s, GNC)

Investment Highlights

SCOLR Pharma, Inc.

Amex:  DDD

Value Driving Opportunities

Program Initiation and Development with funding raised from

$15.0 million equity financing in February 2005

Initiation and completion of each step towards product

commercialization

Agreements with licensing and/or marketing partners

Expansion of Intellectual Property

Five new patent applications in ’04

Fourth U.S. Patent Issued and Several full-Patent

Applications Submitted in ’05

Several new patent applications planned for ‘06

Investment Highlights

SCOLR Pharma, Inc.

Amex:  DDD

Investment Highlights

Historically Rich Market Valuations for Successful

Companies

An analysis of selected companies operating in the

same space have considerably higher valuations

Andrx

(Nasdaq: ADRX): 

$1.28 billion

Biovail (NYSE: BVF)         

$4.00 billion

Depomed

(Nasdaq: DEPO)

$274.5 million

Flamel

(Nasdaq: FLML):   

$529.5 million

Impax

(Nasdaq: IPXLE):     

$605.3 million

Pozen

(Nasdaq: POZN):

$451.3 million

Skyepharma

(Nasdaq: SKYE) 

$507.3 million

Approx. Valuations as of Jan. 23, 2006

SCOLR Pharma, Inc.

Amex:  DDD

Target 

ID

Target

Validation

Product

Formulation

Lead

Optimization

Pre-

Clinical

Clinical -

Regulatory

Identification

CDT Product Development

Final Product

Partner

Evaluation

Commitment

|

1-2

Months

|

8-14

Months

|

24

–

36

Mos.

|

Market

Business Model Overview

Markets

•

New

Chemical

Entity

•

Rx,

OTC

Drug

-

Exclusive -

New Formulation (NDA)      

-

Generic -

New Use (NDA)

-

BioEquiv. (ANDA)

•

Dietary

Supplements

Identification Criteria

•

Partnership Interest

•

Market Size

•

Exclusivity Status

•

Competition

•

Cost (Dev.       Market)

•

Time to Market

SCOLR Pharma, Inc.

Amex:  DDD

Peer Group Comparison

UNKNOWN

Polymer

2-3, tablet

12 or more

36 or more

36 or more

36 or more

12-20

18 or more

2-3

Estimated

Manufacturing

Steps

Multiple

manufacturing

steps,

complex

processes

Multi-

Particulate,

erosion,

dissolution

Capsule,

pellets

No

Biovail

Specialized

manufacturing

equipment,

complex

Multi-Layered

Tablet,

Hydrophilic

Matrix,

Swellable

polymer

matrix

Multilayered

tablet

Yes

Skyepharma

Multiple

manufacturing

steps,

complex

processes

Multi-

Particulate,

erosion,

dissolution

Coated

pellets

No

Flamel

Multiple

manufacturing

steps,

complex

processes

Multi-

Particulate,

erosion,

dissolution

Capsule or

coated pellets

Yes

Elan

Labopharm

Andrx

Alza

SCOLR

Special

engineered

polymer,

limited

source,

availability

and

application

Requires

special

manufacturing

with multiple

steps

Complex,

payload

restrictions,

fragile, short

exclusivity

Limitations*

*As compared with  

SCOLR Pharma.

Hydrophilic

Matrix,

Swellable

polymer

matrix

Hydrophilic

Matrix,

Swellable

polymer

matrix

Reservoir

Device,

Osmotic

pump

Hydrophilic

Matrix,

Swellable

polymer

matrix

Mode of Action

Tablet

Tablet

Coated

Bilayer Tablet

Tablet

Dosage Form

No

No

Yes

Yes

Wide

Range

of 

Drugs Tested

SCOLR Pharma, Inc.

Amex:  DDD

Current OTC and Rx Development Targets

$> 4 billion Market

(1)

$ 1 billion

(Global)

-

Animal Study Positive

-

Human Pilot

Study

dosing complete Q-4, ‘05,

-

Data analysis Q-1, ‘06

-

Less

Drug

for

similar

results

(2)

-

Faster absorption

(2)

-

1 tablet vs. 3 every 24 hrs.

-

Simplified Manufacturing

-

Lower Cost

-

Patent Protected

Rx Anti-Nausea

CDT –

ER

Ondansetron

$ 1 billion

(Global)

-

Animal Study

Positive

-

Human Pilot Studies  

completed,

Q-3, 2005

-

Results positive

-

Less

Drug

for

similar

results

(2)

-

Simplified Manufacturing

-

Lower Cost

-

Patent Protected

Rx Osteoporosis

CDT –

IR Raloxifene

$ 1 billion

(U.S.)

-

ANDA Trials Completed,

Q-2,05

-

ANDA Submission planned

2006

-

1/3

size

of

current

OTC

Products

-

Lower Cost

-

Patent Protected

OTC

Decongestant

CDT –

12 hr

Pseudoephedrine

$ 8 billion

(Global OTC

analgesic.)

-

Licensed to WCH, Q4, ‘05

-

1

Extended

Release

OTC

Ibuprofen

-

1 tablet vs. 3 every 12 hrs.

-

Lower Cost

-

Patent Protected

OTC Analgesic

CDT –

12 hr Ibuprofen

Current  Market

Estimate

(1)

Status

Potential Advantages

Application

Lead Products

Notes: 

(1)

Market Data Sources –

IMS, Data Monitor, Company Disclosures, SCOLR

Estimates.

(2)

Based on 2004 Animal Study Findings and Initial 2005 Clinical Results

st

rd

SCOLR Pharma, Inc.

Amex:  DDD

Representative Participant

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

0.0

5.0

10.0

15.0

20.0

25.0

30.0

Time (hours)

CDT Formulation

CDT Formulation

CDT Formulation

200mg OTC control

600mg Rx control

Current Development Targets -

Ibuprofen

Initial

Ibuprofen

clinical

results

were

favorable

and

led

to

license

of

CDT

applications

for

ibuprofen

products

to

WCH

(Dec.

’05).

Achieves 12 hour extended release in humans.

Shown to be bioequivalent (AUC) to reference OTC and Rx tablet.

SCOLR Pharma, Inc.

Amex:  DDD

Initial Pseudoephedrine Results Positive

Confirms 12 hours Extended Release in Humans

Bioequivalent to OTC Reference Product

STUDY AAI-US-294

LEAST-SQUARES MEAN PSEUDOEPHEDRINE PLASMA CONCENTRATIONS

(N=12)

Under Fasted Conditions

0

50

100

150

200

250

300

350

0

2

4

6

8

10

12

14

16

18

20

22

24

Hours After Dose

TEST

REFERENCE

Current Development Targets -

Pseudoephedrine

SCOLR Pharma, Inc.

Amex:  DDD

48%

59%

80%

Percent of

Variation

from Mean

Value

84%

20048.25

304.09

CDT®

“B”

45 mg

(Non-Optimized)

100%

23952.96

489.24

Evista®

60 mg

(Control)

65%

15455.76

414.14

45 mg Control

(Conventional Tablet)

AUC

0-inf

(picograms/ml)

Calculated Value

Percent of AUC

as compared to

Evista®

Control

Cmax

Formulation

Conclusions:

1.

CDT shown to be a viable alternative to complex solubility and/or permeability

enhancing practices.

2.

Pilot results indicate ability to reduce variability and increase absorption of

raloxifene HCl, as compared to controls. 

Note: Study conducted and results provided by contract clinical research organizations using conventional

methods and practices.

Current Development Targets -

Raloxifene

SCOLR Pharma, Inc.

Amex:  DDD

In Vivo

validation of Amino Acid Platform/Technology

Increased Bioavailability of Ondansetron in rats

Table –Mean Pharmacokinetic Parameters

49.6

81.7

43.0

50.9

2435.5

2450.7

Ondansetron

Control Tablet

3.8

10.8

123.3

105.0

10332.24

7116.0

Ondansetron

Amino Tablet

Std.

Dev.

Mean

Std.

Dev.

Mean

Std. Dev.

Mean

T

max

(min)

C

max

(ng/mL)

AUC

2h

(min*ng/mL)

Formulation

Current Development Targets -

Ondansetron

Initial Human Pilot Study

Dosing Completed Q4, ’05

Data analysis Q1, ‘06

SCOLR Pharma, Inc.

Amex:  DDD

Licensable Portfolio &

Post Menopausal:

In Clinic

Immediate Release & ER tablets

Osteoporosis

-

Raloxifene

Preclinical

24 hour sustained release tablets

Ca channel Blocker

-

Verapamil

Preclinical

24 hour sustained release tablets

Ca channel Blocker

-

Nifedipine

Preclinical

24 hour sustained release tablets

Ca channel Blocker

-

Diltiazem HCl

Preclinical

24 hour sustained release tablets

Beta-Blocker

-

Metoprolol

Preclinical

24 hour sustained release tablets

Beta-Blocker

-

Propranolol

Preclinical

12 hour sustained release tablets

Antilipidemic

-

Niacin

Cardiovascular :

Preclinical

12 hour sustained release tablets

Pain Management

-

Combination

Preclinical

12/24 hour sustained release tablets

Pain Management

-

Tramadol

Preclinical

12 hour sustained release tablets

Pain Management

-

Acetaminophen

Licensed

12 hour sustained release tablets

Pain Management

-

Ibuprofen

Analgesics :

STATUS

DESCRIPTION

INDICATION

NAME

SCOLR Pharma, Inc.

Amex:  DDD

Preclinical

24 hour sustained release tablets

Decongestant

-

Pseudoephedrine

Cough-Cold :

Clinic Done

12 hour sustained release tablets

Decongestant

-

Pseudoephedrine

Preclinical

12/24 hour sustained release tablets

Decongestant/Anti-

histamine

-

Pseudoephedrine/

Loratadine

Preclinical

12 hour sustained release tablets

Decongestant/Pain

Management

-

Combination

Preclinical

12 hour sustained release tablets

Asthma, Bronchodilator

-

Theophylline

Pulmonary :

In Clinic

24 hour sustained release tablets

Nausea

-

Ondansetron HCl

Preclinical

24 hour sustained release tablets

Motion Sickness

-

Dimenhydrinate

Nausea :

Preclinical

12 hour sustained release tablets

Diabetes

-

Metformin

Preclinical

24 hour sustained release tablets

Diabetes

-

Glipizide

Diabetes :

STATUS

DESCRIPTION

INDICATION

NAME

Licensable Portfolio &

SCOLR Pharma, Inc.

Amex:  DDD

Dietary  Supplements:

On Market

12 hour and Once daily tablets

500/400

-Glucosamine/Chondroitin

On Market

12 hour sustained release tablets

300/250/300

-Glucosamine/Chondroitin/MSM

On Market

12 hour sustained release tablets

250/250

-Glucosamine Complex

On Market

(ADM)

Custom designed Pre-blends

various

-Novasoy™

Available

10 hour sustained release tablets

200

-Caffeine

On Market

12 hour sustained release tablets

250

-Niacin

On Market

12 hour sustained release tablets

640 (500)

-Ester C™

On Market

12 hour sustained release tablets

500

-Vitamin C

STATUS

DESCRIPTION

STRENGTH

(mg)

NAME

Marketed or Licensed Dietary Supplements

SCOLR Pharma, Inc.

Amex:  DDD

2006 Objectives

Submission

of

Regulatory

Applications

for

Ibuprofen

and Pseudoephedrine

Identification

of

additional

targets

and

clarify

regulatory

pathway

Continued

development

of

amino

acid

technology

Structure

and

execute

pharmaceutical

agreements  

(including

feasibility,

licensing,

royalty

and

milestone

payments)

Continue

to

expand

and

enhance

presence

as

novel

drug delivery

company/resource

File

additional

patents

Secure

additional

capital

SCOLR Pharma, Inc.

Amex:  DDD

SCOLR Pharma

Opportunity

Large, growing markets

Unique, broadly applicable, patented technology  

platform w/ important benefits

Expanding prescription and OTC pipeline with

several clinical and pre-clinical candidates

Royalty revenues from existing products

Value driving milestones

TM

SCOLR Pharma, Inc.

Amex:  DDD

SCOLR Pharma, Inc.

3625

132

nd

Ave

SE,

#300

Bellevue, WA. 98006

www.scolr.com

TM

CDT®

is a registered trademark of SCOLR Pharma, Inc.

SCOLR & CDT logo and design are trademarks of SCOLR Pharma, Inc.